TS ANTITIJELA \u0026 MIKO

(16:9)

TS ANTITIJELA: Corona drmeš

(8:48)

TWiV 975: Crossing the Ts with Daniela Weiskopf

(1:36:6)

EBMT-EHA CAR T-cell highlights: new indications, new CAR-Ts \u0026 the microbiota’s impact on outcomes

(2:26)

TS Biomarkers, Clinical Diagnostics, B.R.A.H.M.S - Fully Automated Manufacturing

(3:24)

Exploring the applications of CAR-Ts beyond hematology and oncology

(1:39)

Using dual-targeting CAR-Ts to overcome CAF-induced CAR-T resistance in multiple myeloma

(3:3)

Combining CAR-Ts \u0026 bispecific antibodies

(2:22)

Selecting between CAR-Ts and bispecifics for patients with HRMM who are triple-class exposed

(1:58)

CARAMBA-1: a Phase I/IIa trial of autologous SLAMF7 CAR-Ts in multiple myeloma

(1:36)

Young EBMT \u0026 EHA Ambassadors: the basic science behind CAR-Ts

(1:16)

Access to bispecifics and CAR-Ts for multiple myeloma in Brazil

(57)

A study investigating the efficacy of dual-targeting bispecifics/CAR-Ts in a large cohort

(2:38)

Latest advances in immunotherapy for multiple myeloma: targets, alloCAR-Ts \u0026 immunomodulatory drugs

(1:16)

Basic principle of Immunohistochemistry: the dos and don’ts│ Dr. Carine Nguemeni.

(1:5:25)

Linvoseltamab versus teclistamab for TCE RRMM and the sequencing of bispecifics with CAR-Ts

(5:30)

Rationale for using CAR-Ts to treat chronic hepatitis B

(1:12)

CAR-Ts: Next Generation Products and Strategies? Upfront, High Risk?

(21:39)

Advantages and current status of off-the-shelf CAR-Ts

(1:8)

Approved CAR-Ts in R/R ALL: tisa-cel and brexu-cel

(5:24)